A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment

BACKGROUND: About 50% of patients with colorectal cancer are destined to develop hepatic metastases. Radical resection is the most effective treatment for patients with colorectal liver metastases offering five year survival rates between 36-60%. Unfortunately only 20% of patients are resectable at...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Snoeren, Nikol, Voest, Emile E, Bergman, Andre M, Dalesio, Otilia, Verheul, Henk M, Tollenaar, Rob AEM, van der Sijp, Joost RM, Schouten, Sander B, Rinkes, Inne HM Borel, van Hillegersberg, R
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2010
נושאים:
Study Protocol
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2958953/
https://ncbi.nlm.nih.gov/pubmed/20937118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-10-545
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים